Application of rhFGF21 in preparation of medicine for treating diabetes accompanied with depression

rhFGF21 produced through genetic engineering is used to treat diabetes accompanied by depression, solving the problem that existing drugs are difficult to reduce blood sugar and improve depression at the same time, and achieving effective treatment for diabetic mice, including lowering blood sugar, improving depression, and antioxidant response. Multiple effects of stimulating and protecting the blood-brain barrier.

CN118903382APending Publication Date: 2024-11-08THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411234500.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-04
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing drugs for treating depression accompanied by diabetes are difficult to effectively reduce blood sugar and improve depression symptoms at the same time, and have adverse effects on oxidative stress and blood-brain barrier in the brain.

Method used

rhFGF21 produced by genetically engineered, by prolonging its half-life and reducing precipitation, it is used to prepare drugs for treating diabetes-related depression. rhFGF21 has multiple effects of antioxidant stress, improving endothelial cell function, blood-brain barrier protection and neuronal expression. .

Benefits of technology

rhFGF21 can effectively reduce blood sugar in diabetic mice, improve depression-like behavior, reduce oxidative stress, protect the blood-brain barrier, increase blood flow perfusion in the brain and neuronal PSD95 expression, which is more common than the existing drugs fluoxetine and insulin Strong antioxidant stress and protective effects of brain endothelial cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903382A_ABST
    Figure CN118903382A_ABST
Patent Text Reader

Abstract

The invention discloses an application of rhFGF21 in preparation of a medicine for treating diabetes accompanied with depression, the rhFGF21 has dual effects of reducing blood sugar of diabetes and improving depression-like behaviors of diabetes, has an anti-oxidative stress effect, can improve endothelial cell dysfunction and blood-brain barrier damage induced by high sugar and oxidative stress, and meanwhile, can be used for preparing medicines for treating diabetes accompanied with depression, and can be used for preparing medicines for treating diabetes accompanied with depression. The traditional Chinese medicine composition can relieve high-glucose-induced astrocyte over-activated hyperplasia and neuronal PSD95 expression reduction and improve high-glucose-induced glutamic acid metabolic disorder and lactic acid metabolic disorder, so that the diabetes accompanied depression behavior is improved, and compared with existing medicines fluoxetine, insulin and rhFGF21, the traditional Chinese medicine composition has more diverse anti-depression mechanisms.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of biomedicine, and in particular to the use of rhFGF21 in preparing a drug for treating diabetes-associated depression. Background Art

[0002] Diabetes is a common chronic disease, and its incidence has been increasing over the past two decades. It is a systemic, metabolic disease characterized by increased blood sugar levels, and metabolic disorders caused by insufficient secretion or dysfunction of insulin in the body. As blood sugar increases, patients will experience clinical manifestations of polyuria, polydipsia, polyphagia, and weight loss. Long-term diabetes can lead to cerebral microvascular complications, macrovascular complications, and neuropsychiatric complications.

[0003] Depressive symptoms are one of the most common complications of diabetes. Depressive symptoms reduce the compliance of diabetic patients with hypoglycemic drugs, aggravate the metabolic disorders of diabetic patients, and increase the risk of death in diabetic patients. Therefore, early identification of depressive symptoms associated with diabetic patients and appropriate treatment are very important for improving the prognosis and quality of life of diabetic patients.

[0004] At present, the drugs for treating diabetes-associated depression mainly include antidepressants and hypoglycemic drugs. The first-choice drugs for treating depression symptoms in diabetic patients, such as serotonin reuptake inhibitors, affect blood sugar control, aggravate hyperglycemia, and have a slow onset of action and poor compliance with medication. These problems highlight the urgency of finding new pharmacological targets for treating diabetes-associated depression.

[0005] Finding a drug that can rapidly improve depressive symptoms and hyperglycemia in diabetic patients is an important challenge facing clinical and basic researchers. Summary of the invention

[0006] In order to solve the problems existing in the above-mentioned background technology, the present invention provides a use of rhFGF21 in the preparation of a drug for treating diabetes-associated depression. rhFGF21 has the dual effects of lowering blood sugar in diabetes and improving its depressive-like behavior. rhFGF21 has an antioxidant stress effect. It can improve endothelial cell dysfunction and blood-brain barrier damage induced by high sugar and oxidative stress. At the same time, it reduces the excessive activation and proliferation of astrocytes and the reduced expression of neuronal PSD95 induced by high sugar, improves the glutamate metabolism disorder and lactate metabolism disorder induced by high sugar, thereby improving the depressive behavior associated with diabetes. Compared with the existing drugs fluoxetine and insulin, the antidepressant mechanism of rhFGF21 is more diverse.

[0007] In order to achieve the above object, the present invention adopts the following technical solutions:

[0008] The present invention provides use of rhFGF21 in preparing a medicine for treating diabetes-associated depression.

[0009] The half-life of natural FGF21 in vivo is short (0.5-1 hour), it can be cleaved by serum proteases, and easily precipitates to form insoluble aggregates, which limits its clinical application. The rhFGF21 produced by genetic engineering technology has a longer half-life than natural FGF21 and is not easy to precipitate. In the present invention, STZ-induced type I diabetes model mice were established, and then the therapeutic effect of rhFGF21 on the depressive-like behavior associated with diabetic model mice was detected, and its potential mechanism was explored.

[0010] The results of the test show that rhFGF21 has the dual effects of lowering blood sugar and improving depressive-like behavior. It has neurobiological effects in the brain such as protecting neurovascular units, resisting oxidative stress, improving glutamate-glutamine cycle disorders and lactate metabolism disorders.

[0011] Furthermore, the rhFGF21 is used to prepare a drug for lowering blood sugar in diabetics and improving their depressive-like behavior.

[0012] Furthermore, the rhFGF21 is used to prepare a drug for alleviating high glucose-induced neurovascular unit damage.

[0013] Furthermore, the rhFGF21 is used to prepare a drug having an anti-oxidative stress effect.

[0014] Furthermore, the rhFGF21 is used to prepare a drug for upregulating the Nrf2 / HO-1 pathway in the brain, increasing the activities of CAT and SOD in the brain, and reducing the content of MDA.

[0015] Furthermore, the rhFGF21 is used to prepare a drug for improving endothelial cell dysfunction and blood-brain barrier damage induced by high glucose and oxidative stress.

[0016] Furthermore, the rhFGF21 is used to prepare a drug for increasing cerebral blood perfusion.

[0017] Furthermore, the rhFGF21 is used to prepare a drug for alleviating the high glucose-induced decrease in the expression of tight junction proteins ZO-1, Claudin5, and pericyte marker PDGFβ and the over-activated proliferation of astrocytes.

[0018] Furthermore, the rhFGF21 is used to prepare a drug for improving high glucose-induced glutamate metabolism disorder and lactate metabolism disorder in the brain.

[0019] Furthermore, the rhFGF21 is used to prepare a drug for increasing the expression of neuronal synaptic protein PSD95.

[0020] Furthermore, the drug for treating diabetes-associated depression contains rhFGF21 as an active ingredient.

[0021] The drug for treating diabetes-associated depression may further contain pharmaceutically acceptable carriers or excipients.

[0022] The drug for treating diabetes-associated depression is prepared into pharmaceutically acceptable dosage forms, including tablets, capsules, injections, pills, powders, ointments and pills.

[0023] Compared with the prior art, the present invention has the following beneficial effects:

[0024] In the present invention, STZ-induced type I diabetes model mice were established, and then the therapeutic effect of rhFGF21 on diabetic model mice with depressive-like behavior was detected, and its potential mechanism was explored. The results of the test showed that rhFGF21 has the dual effects of reducing blood sugar in diabetic mice and improving their depressive-like behavior. Specifically, rhFGF21 reduces blood sugar in diabetic mice and relieves the level of oxidative stress in the brain of diabetic mice, reducing endothelial cell damage and dysfunction caused by oxidative stress. At the same time, rhFGF21 increases the expression of tight junction proteins ZO-1, claudin5 and pericyte marker PDGFβ in the blood-brain barrier of diabetic mice, reduces the overactivation of astrocytes in the brain of diabetic mice, glutamate metabolism disorders and lactate metabolism disorders, increases the expression of neuronal synaptic protein PSD95, and finally improves the depressive-like behavior of diabetic mice. Compared with fluoxetine and insulin, rhFGF21 has stronger anti-oxidative stress, increases whole brain blood perfusion, improves brain endothelial cell dysfunction and protects the blood-brain barrier, suggesting that it has advantages in the treatment of cerebrovascular diseases. At the same time, improving lactate metabolism dysfunction may be one of the important mechanisms by which hypoglycemic drugs improve the depressive-like behavior of diabetic mice. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] The present invention is further described in detail below with reference to the accompanying drawings and specific embodiments.

[0026] Figure 1 The results of the open field test (OFT), tail suspension test (TST) and forced swim test (FST) of six groups of mice are shown;

[0027] Figure 2 The expression levels of endogenous FGF21 in the hippocampus (A) and prefrontal cortex (B) of the six groups of mice;

[0028] Figure 3 is the cerebral blood perfusion of six groups of mice;

[0029] Figure 4The expression levels of vWF, tPA, and PAI-1 in the hippocampus and prefrontal cortex of the six groups of mice;

[0030] Figure 5 The expression levels of eNOS in endothelial cells of the hippocampus and prefrontal regions of the six groups of mice and the total expression level of eNOS;

[0031] Figure 6 The expression levels of ZO-1, claudin5, PDGFβ, and AQP4 in the hippocampus and prefrontal cortex of the six groups of mice;

[0032] Figure 7 The numbers of GFAP-positive astrocytes in the hippocampus and prefrontal cortex of the six groups of mice;

[0033] Figure 8 The numbers of NeuN-positive neurons in the hippocampus and prefrontal cortex, and the expression levels of synaptic proteins PSD95 and TSP-1 in the six groups of mice;

[0034] Fig. 9 The activities of CAT and SOD, and the contents of GSH and MDA in the hippocampus and prefrontal cortex of the six groups of mice after treatment;

[0035] Fig.10 The expression levels of Nrf2, NQO1, SOD2, and HO-1 in the hippocampus and prefrontal cortex of the six groups of mice after treatment;

[0036] Fig.11 The expression levels of glutamate transporters GLAST and GLT-1 in the hippocampus and prefrontal cortex of mice in the six groups after treatment;

[0037] Fig.12 The expression levels of lactate transporters MCT1 and MCT4 in the hippocampus and prefrontal cortex of mice in the six groups after treatment;

[0038] Fig.13 Diagram of the neurobiological mechanism by which rhFGF21 improves diabetic mice. DETAILED DESCRIPTION

[0039] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0040] 1. Experimental Materials

[0041] 1.1 Experimental animals

[0042] Male C57BL / 6 mice weighing 20-25 g and aged 8 weeks were selected. The mice were purchased from Beijing Weitonglihua Experimental Animal Technology Co., Ltd. and raised in the SPF animal room of Wenzhou Medical University School of Psychiatry with a controlled indoor environment (temperature of 23±2°C, relative humidity of 55±10%, 12h light-dark cycle).

[0043] 1.2 Instruments

[0044] Yuyue blood glucose meter was purchased from Jiangsu Yuyue Medical Equipment Co., Ltd.;

[0045] The weighing scale, open field, elevated plus maze, Y maze, tail suspension apparatus, and forced swimming apparatus were purchased from Reward;

[0046] The small animal behavior video analysis software smart is from the Spanish company Panlab.

[0047] 2. Experimental Methods

[0048] 2.1 Establishment of diabetic mouse model and animal grouping

[0049] 2.1.1 Establishment of STZ-induced diabetic animal model

[0050] The mice that had been kept and observed for one week were randomly divided into a control group (CN group) and a modeling group (DM group). The two groups of animals were intraperitoneally injected with an equal volume (1mL / 100g) of solvent (sodium citrate solution) or STZ (100mg / kg) once a day for two consecutive days. The day before the injection, the mice were fasted for 12 hours at night, but water was not allowed. The blood sugar of the mice was first tested at 72 hours after the second injection. Blood sugar higher than 16.7mmol / L was considered to be a successful modeling.

[0051] 2.1.2 Animal grouping

[0052] The mice that were raised and observed for one week were randomly divided into 6 groups, namely, normal saline group (NS group, N=8), rhFGF21 group (FGF21 group, N=8), diabetes + normal saline group (DM+NS group, N=8), diabetes + rhFGF21 group (DM+FGF21 group, N=8), diabetes + fluoxetine group (DM+Flu group, N=8), and diabetes + insulin group (DM+Ins group, N=8). Among them, the preparation methods of diabetic model mice in the four groups of DM+NS group, DM+FGF21 group, DM+Flu group, and DM+Ins group are shown in 1.

[0053] The treatment methods for different groups are as follows:

[0054] In the NS group, normal control mice were given the same volume of normal saline by intraperitoneal injection twice a day for 2 consecutive weeks after being fed for 8 weeks and completing a 1-week behavioral test.

[0055] In the FGF21 group, normal control mice were fed for 8 weeks and completed a one-week behavioral test. Then, they were given 0.4 mg / kg / d of rhFGF21 (0.1 mg / ml rhFGF21 injection was prepared with normal saline as the solvent) by intraperitoneal injection, twice a day, for 2 consecutive weeks.

[0056] In the DM+NS group, STZ-induced diabetic model mice were fed for 8 weeks and completed a 1-week behavioral test. Then, the same volume of normal saline was intraperitoneally injected twice a day for 2 consecutive weeks.

[0057] In the DM+FGF21 group, after STZ-induced diabetic model mice were fed for 8 weeks and completed a one-week behavioral test, they were given 0.4 mg / kg / d of rhFGF21 (0.1 mg / ml rhFGF21 injection prepared with normal saline as the solvent) by intraperitoneal injection, twice a day, for 2 consecutive weeks.

[0058] In the preliminary experiment, different concentrations of rhFGF21 (0.1 mg / kg, 0.4 mg / kg) were tried twice a day for 14 consecutive days. It was found that rhFGF21 0.4 mg / kg had a good therapeutic effect on the depressive-like behavior of diabetic mice. Therefore, this dose of rhFGF21 was used as the therapeutic dose in the formal experiment.

[0059] In the DM+Flu group, STZ-induced diabetic model mice were fed for 8 weeks and completed a one-week behavioral test. Then, they were given 10 mg / kg / d of fluoxetine (1 mg / ml fluoxetine solution prepared with normal saline as solvent) by gavage once a day for 2 consecutive weeks.

[0060] In the DM+Ins group, after the STZ-induced diabetic model mice were fed for 8 weeks and completed a one-week behavioral test, they were given 1 U / kg insulin (diluted with normal saline to make 0.2 U / ml insulin diluent) by subcutaneous injection, twice a day, for 2 consecutive weeks.

[0061] 2.2 Blood glucose and body weight measurement

[0062] The blood glucose and body weight of mice were detected and recorded before drug treatment (day 0) and during drug treatment (days 3, 6, 9, and 12).

[0063] 2.3 Animal behavior testing

[0064] After two weeks of drug treatment, behavioral tests such as open field test, tail suspension test and forced swimming test were performed on mice in different groups.

[0065] 1) Open field test (OFT)

[0066] A homemade open box with a length of 50 cm, a width of 50 cm, and a height of 30 cm was used. The walls of the box were painted black, and the bottom of the box was evenly divided into 9 square areas. During the test, the mouse was placed in the center of the bottom of the wooden box and allowed to move freely for 10 minutes. Smart3.0 software recorded the total distance the mouse moved. After each mouse test, the remaining feces and urine were removed, and the bottom and walls of the open field were wiped with alcohol to eliminate odors.

[0067] 2) Tail suspension test (TST)

[0068] Stick the tape to the back 1 / 3 of the mouse's tail, and hang the mouse on a fixed stand, with the mouse's head about 15 cm away from the table. Record and time it, and stop after 6 minutes. Count the immobility time in the last 4 minutes. After each mouse is tested, wipe it with alcohol to remove the remaining feces and urine.

[0069] 3) Forced swim test (FST)

[0070] The mice were placed in a glass tank (45 cm high, 18 cm bottom diameter, 30 cm water depth) with a water temperature of 23-25°C for 6 minutes. The first 2 minutes were considered as the adaptation time, and the immobility and struggling behaviors of the mice were recorded for 4 minutes. The mice were considered immobile if they were immobile on the water surface, or occasionally paddled their limbs to keep their heads above the water surface. The mice were considered struggling if they used their front paws to climb up along the inner wall.

[0071] 2.4 Laser speckle blood flow imaging to record mouse cerebral blood flow

[0072] 1) Anesthetize the mouse with 1.25% tribromoethanol, remove the hair on the mouse head with scissors, disinfect with iodine, and cut the skin on the head with scissors to expose the entire brain bone window.

[0073] 2) Fix the mouse on a fixator, turn on the laser speckle blood flow imager, detect the whole brain blood flow of the mouse and record the relevant data.

[0074] 2.5 Brain tissue protein extraction and protein quantification

[0075] 1) Anesthetize the mouse with 1.25% tribromoethanol, perfuse with 1×PBS, remove the mouse brain, place all tissues on ice, use forceps to quickly separate the hippocampus tissue and prefrontal lobe tissue, place them in marked sterile EP tubes, and store them in a -80°C refrigerator.

[0076] 2) When extracting brain tissue, first take out the brain tissue from the -80°C refrigerator, add the corresponding RIPA lysis buffer, PSMF and phosphatase inhibitor according to the weight of the tissue block at a ratio of 100:1:1, and grind it thoroughly with a high-throughput tissue homogenizer (pre-cooled in advance) at 60 Hz for 45 s two to three times.

[0077] 3) The homogenate was placed on ice for 30 min to allow for complete lysis, and the centrifuge was precooled.

[0078] 4) The lysed homogenate was centrifuged at 12000 rpm for 20 min at 4°C.

[0079] 5) Take the supernatant and quantify the protein using the BCA method.

[0080] 6) Add 5×SDS-PAGE Loading Buffer and mix well. Heat in a water bath for 7-10 min (100°C). Perform western blot directly or store at -20°C for later use.

[0081] 2.6 Western blot

[0082] 1) Prepare gel: According to the SDS-PAGE electrophoresis gel preparation table, prepare the corresponding separation gel and concentrated gel, 5% electrophoresis concentrated gel, 8% electrophoresis separation gel, 10% electrophoresis separation gel, and 12% electrophoresis separation gel. First, mix the separation gel thoroughly and add it to the gel plate. After pouring, press it flat with anhydrous ethanol. After the separation gel is completely solidified, remove the anhydrous ethanol, use filter paper to absorb the excess anhydrous ethanol, and quickly add the prepared concentrated gel, and quickly insert a comb of appropriate size. After the concentrated gel solidifies, it can be used directly or stored at 4°C;

[0083] 2) Electrophoresis: Install the electrophoresis device, add freshly prepared 1× electrophoresis solution, pull out the comb and load the sample according to the experimental needs, and start electrophoresis after confirming that everything is correct. Select the voltage of 80V for the concentrated gel, and when the sample is at the interface of the separation gel and concentrated gel, change the voltage to 120V. Stop electrophoresis after the target band is separated; prepare 1× transfer solution and pre-cool it at 4℃ for use;

[0084] 3) Transfer: Cut the PVDF membrane of appropriate size in advance, and activate the membrane with methanol until it is transparent (about 1 minute). Pour the transfer solution into the porcelain plate, and place it in the order of the plywood blackboard, sponge, two layers of filter paper, gel with excess cut off, PVDF membrane, two layers of filter paper, sponge, and plywood whiteboard. Pay attention to keep the gel moist, and ensure that no bubbles are introduced between the gel and the membrane. Install the transfer device, pour in a sufficient amount of transfer solution, and put it in an ice box. Use a constant voltage of 100V to transfer the membrane for 70 minutes (adjust the transfer time according to the molecular weight of the corresponding target protein). Keep the temperature low throughout the process;

[0085] 4) Blocking: Take out the transferred membrane, wash off the transfer solution with 1×TBST, and then place the membrane in a rapid blocking solution for 20 minutes (adjusted according to room temperature);

[0086] 5) Antibody incubation: Wash 3 times with 1×TBST, cut the PVDF membrane of appropriate size according to the molecular weight of the target protein, and put it into the incubation box containing the corresponding antibody. Incubate overnight at 4°C on a shaker at low speed to recover the primary antibody, and elute the primary antibody with 1×TBST at room temperature for 10 min × 3 times.

[0087] Then, the corresponding species secondary antibodies were incubated at room temperature for 60 min.

[0088] When exploring whether rhFGF21 has an improving effect on high glucose-induced neurovascular unit damage, the primary antibodies used are as follows: rabbit eNOS (27120-1-AP, Proteintech, 1:1000), rabbit anti-vWF (27186-1-AP, Proteintech, 1:10000), rabbit anti-tPA (10147-1-AP, Proteintech, 1:2000), mouse anti-PAI-1 (66261-1-Ig, Proteintech, 1:20000) ), rabbit anti-PDGFβ(13449-1-AP, Proteintech, 1:1000), rabbit anti-ZO-1(21773-1-AP, Proteintech, 1:10000), rabbit anti-Claudin5(29767-1-AP, Proteintech, 1:10000), mouse anti-GADPH(60004-1-lg, Proteintech, 1:10000) and mouse anti-β-actin(MABT825, sigma, 1:5000). When exploring the neurobiological mechanism of rhFGF21 improving the depressive-like behavior of diabetic mice, the primary antibody information used is as follows:

[0089] Rabbit anti-Nrf2 (16396-1-AP, Proteintech, 1:1000), rabbit anti-SOD2 (66474-1-lg, Proteintech, 1:10000), rabbit anti-NQ 01 (11451-1-AP, Proteintech, 1:2000), rabbit anti-HO-1 (10701-1-AP, Proteintech, 1:3000), rabbit anti-GLAST (ab416, Abcam, 1:1000), rabbit anti-GLT-1 (22515-1-AP, Proteintech, 1:1000), rabbit anti-MCT 1 (20139-1-AP, Proteintech, 1:10000), rabbit anti-MCT 4 (22787-1-AP, Proteintech, 1:10000).

[0090] The secondary antibodies used were the same as follows: mouse anti-IgG-HRP (SA00001-1, Proteintech, 1:10000), rabbit anti-IgG-HRP (SA00001-2, Proteintech, 1:10000). The secondary antibodies were discarded and eluted with 1×TBST for 10 min×3 times.

[0091] 6) Exposure: Develop according to the instructions of ECL developer and perform quantitative analysis using Image J software.

[0092] 2.7 Frozen sections

[0093] 1) Mice were anesthetized with tribromoethanol and perfused with 1×PBS. After the blood was completely perfused, the perfused brain tissue was taken and immersed in 4% PFA for 72 h;

[0094] 2) Dehydrate with 15%-30% sucrose gradient, and the brain can be used for frozen sections after it sinks completely;

[0095] 3) Embed the brain tissue with OCT according to the cross-section requirements and place it at -80℃ for 10 minutes for fixation;

[0096] 4) Slice according to the operating instructions of the freezing microtome, with a thickness of 10 μm. Pre-cool the slides in advance and store the slices at -20℃.

[0097] 2.8 Immunofluorescence histochemistry of frozen sections

[0098] 1) Take 10 μm frozen sections of mouse brain tissue and place them at room temperature to dry for 5-10 minutes, then place them in a 55°C oven for 30 minutes to make the tissue stick more firmly;

[0099] 2) Wash the slides with 1×PBS for 5 min × 3 times to remove OCT from the slices;

[0100] 3) Fix with 4% PFA for 30 min, wash with 1× PBS, and perform antigen retrieval according to the condition of the slice;

[0101] 4) 0.3% Triton perforation for 30 min; 5% BSA blocking for 45-60 min (temperature adjusted according to room temperature); incubation with primary antibody prepared with 5% BSA at 4°C overnight.

[0102] When exploring whether rhFGF21 has an improving effect on neurovascular unit damage caused by high glucose, the primary antibodies used are as follows: mouse anti-CD31 (66065-2-Ig, Proteintech, 1:500), rabbit anti-eNOS (27120-1-AP, Proteintech, 1:500), mouse anti-GFAP (60190-1-Ig, Proteintech, 1:500), goat anti-Ibal-1 (ab5076, Abcam, 1:200), rabbit anti-NeuN (26975-1-AP, Proteintech, 1:500).

[0103] When exploring the neurobiological mechanism by which rhFGF21 improves the depressive-like behavior of diabetic mice, the primary antibodies used were as follows: rabbit anti-GLAST (ab416, abcam, 1:200), rabbit anti-GLT-1 (22515-1-AP, Proteintech, 1:3000).

[0104] 5) Wash with 1×PBS for 5 min × 3 times, incubate with fluorescent secondary antibody (1:1000) of corresponding species prepared with 5% BSA at room temperature for 60 min, and wash with 1×PBS for 5 min × 3 times. The secondary antibodies used are as follows: rabbit anti-AlexaFluor594 (A11012, Invitrogen, 1:1000), mouse anti-AlexaFluor488 (A11001, Invitrogen, 1:1000), goat anti-AlexaFluor488 (ab150129, abcam, 1:1000).

[0105] 6) Wipe off excess water stains on the slide, add an appropriate amount of DAPI-containing anti-fluorescence attenuation mounting medium to seal the slide, and then seal the edges with nail polish to prevent the coverslip from slipping and drying. After drying, use a Nikon inverted fluorescence microscope and digital slide scanning system to capture images.

[0106] 2.9 Biochemical kit detection

[0107] Sample pretreatment: Take tissue samples from the hippocampus and prefrontal lobe of mice and accurately weigh the tissue weight, add 9 times the volume of normal saline at a ratio of weight (g): volume (ml) = 1:9, mechanically homogenize under ice water bath conditions, centrifuge at 2500 rpm for 10 minutes, and take the supernatant (10% homogenate supernatant) for measurement (take part of the supernatant to measure the protein concentration).

[0108] 2.9.1 CAT activity detection

[0109] The CAT kit (Nanjing Jiancheng Bioengineering Institute (A007-1-1)) was used according to the operating manual. The absorbance was measured at 405 nm before and after the reaction, and the difference in absorbance was recorded as ΔA.

[0110] Calculation of CAT activity: Definition: One activity unit is the amount of H2O2 decomposed per milligram of tissue protein per second.

[0111] CAT activity in tissue (U / mgprot) = △A × 271 ÷ V 样 ÷T÷Cpr

[0112] Note: 271 is the reciprocal of the slope, a constant, used directly; V 样 : sampling volume, 0.05 ml; T: reaction time, 60 seconds; Cpr: homogenate protein concentration, mgprot / mL (prot refers to protein).

[0113] 2.9.2 SOD activity detection

[0114] Use SOD kit (Nanjing Jiancheng Bioengineering Institute (A001-1-2)) according to the operating manual, mix well, leave at room temperature for 10 minutes, and compare at a wavelength of 550nm, 1cm optical path cuvette, zero with distilled water.

[0115] Calculation of SOD activity

[0116] Total SOD activity (U / mgprot) = ((control OD value - measured OD value) / control OD value)) ÷ 50% × (total volume of reaction solution (ml) / sample volume (ml)) ÷ Cpr

[0117] Cpr: homogenate protein concentration, mgprot / ml (prot refers to protein).

[0118] 2.9.3 GSH content detection

[0119] Preparation of supernatant: Take 0.1 ml of 10% tissue homogenate, add 0.1 ml of reagent in the kit and mix well, centrifuge at 3500 rpm for 10 minutes, and take the supernatant for testing.

[0120] Use the GSH kit (Nanjing Jiancheng Bioengineering Institute (A006-2-1)) according to the operating manual, mix well, let stand for 5 minutes, and measure the absorbance of each well at 405 nm using a microplate reader.

[0121] Calculation of GSH content

[0122] GSH (umol / gprot) = ((measured OD value - blank OD value) / (standard OD value - blank OD value)) × standard tube concentration × sample pre-treatment dilution factor (2 times) ÷ Cpr

[0123] Standard tube concentration: 20umol / L; Cpr: tissue homogenate protein concentration, gprot / L (prot refers to protein).

[0124] 2.9.4 MDA content detection

[0125] Use the MDA kit (Nanjing Jiancheng Bioengineering Institute (A003-1-2)) according to the operating manual, cover the centrifuge tube, poke a small hole in the cover with a needle, mix with a vortex mixer, 95℃ water bath (or boil in a pot with the lid open) for 40 minutes, cool in running water after taking out, and then centrifuge at 3500-4000 rpm for 10 minutes (the centrifugation time needs to be extended below 3000 rpm to ensure complete precipitation). Take the supernatant, 532nm, 1cm optical path, zero with distilled water, and measure the absorbance value of each tube.

[0126] Calculation of MDA content in tissues

[0127] MDA content in tissue (nmol / mgprot) = ((measured OD value - control OD value) / (standard OD value - blank OD value)) × standard concentration (10nmol / ml) ÷ protein concentration of the sample to be tested

[0128] Standard tube concentration: 10nmol / ml; Cpr: tissue homogenate protein concentration, mgprot / ml (prot refers to protein).

[0129] 2.9.5 Glutamate concentration detection

[0130] Take 0.2 ml of 10% homogenate supernatant and add 0.6 ml of reagent 1 in the kit (at a ratio of 1:3), mix thoroughly, centrifuge at 3000-3500 rpm for 10 minutes, and take 0.5 ml of supernatant for testing.

[0131] Use glutamate test kit (Nanjing Jiancheng Bioengineering Institute (A074-1-1)) according to the operation manual, mix well, bath in 37°C water for 40 minutes, take out and zero at 340nm, 1cm light path, double distilled water, measure the absorbance A2 value of each tube, and calculate △A=A2-A1.

[0132] Calculation of glutamate concentration

[0133] Glutamate concentration (umol / gprot) = ((△A 测定 -△A 空白 ) / (△A 标准 -△A 空白 ))×C 标准 ×4÷Cpr

[0134] C 标准: standard concentration, 200 μmol / L; 4: sample pretreatment (adding reagent 1) dilution multiple; Cpr: tissue homogenate protein concentration, gprot / L (prot refers to protein).

[0135] 2.9.6 Lactic acid content detection

[0136] Use lactic acid test kit (Nanjing Jiancheng Bioengineering Institute (A019-2-1)) according to the operation manual, mix well, wavelength 530nm, 1cm light path, distilled water to zero, and measure the absorbance A of each tube.

[0137] Calculation of lactic acid content

[0138] Lactic acid content (mmol / gprot) = ((A 测定 -A 空白 ) / (A 标准 -A 空白 ))×N×C 标准 ÷Cpr

[0139] C 标准 : standard concentration, 3mmol / L; N: sample dilution multiple before testing; Cpr: tissue homogenate protein concentration, gprot / L (prot refers to protein).

[0140] 2.10 Statistical analysis

[0141] In this experiment, except for the animal behavior experiment, all data were analyzed from at least three independent experiments. All data were expressed as Mean ± SD. GraphPadPrism 9 software was selected for data statistical analysis. The t-test was used for comparison between two groups, and the one-way analysis of variance was used for comparison between multiple groups. If the results of the one-way analysis were statistically significant, Bonferroni group comparison was performed. P < 0.05 indicated that the sample difference was statistically significant.

[0142] 3. Experimental Results

[0143] 3.1 rhFGF21 reduces blood glucose in STZ-induced diabetic mice but does not affect their body weight

[0144] The blood glucose of each group of mice was tested before treatment and on the 3rd, 6th, 9th and 12th day after treatment, and the blood glucose levels of each group of mice at different time points were compared. The test results are shown in Table 1. The body weight of the mice was recorded before drug treatment and on the 3rd, 6th, 9th and 12th day after treatment. The test results are shown in Table 2.

[0145] Table 1 Blood glucose levels of mice in each group at different time points

[0146]

[0147] Table 2 Body weight records of mice in different treatment groups before injection and on days 3, 6, 9 and 12 after injection

[0148]

[0149] In Table 1 and Table 2, a P < 0.05, DM + NS vs NS; b P < 0.05, FGF21 vs NS; c P < 0.05, DM + FGF21 vs DM + NS; d P < 0.05, DM+Flu vs DM+NS; e P<0.05, DM+Ins vs DM+NS.

[0150] In Table 1, the blood glucose values ​​of mice in the NS group and the FGF21 group at the same detection time point were compared. The results showed that there was no significant difference in the blood glucose values ​​between the two groups at each detection time point, indicating that rhFGF21 did not affect the blood glucose level of normal mice. The blood glucose values ​​of mice in the DM+FGF21 group were lower than those of mice in the DM+NS group on days 6, 9, and 12 after administration, indicating that rhFGF21 can lower the blood glucose level of diabetic mice. The blood glucose values ​​of DM+Ins mice were lower than those of mice in the DM+NS group on days 9 and 12 after administration, but higher than those of the DM+FGF21 group, indicating that insulin can lower the blood glucose level of diabetic mice, but its hypoglycemic effect is slightly worse than that of rhFGF21. The blood glucose values ​​of the DM+Flu group were not statistically different from those of the DM+NS group on days 6, 9, and 12 after administration, indicating that fluoxetine could not lower the blood glucose level of diabetic mice.

[0151] In Table 2, the body weights of mice in the NS group and the FGF21 group at the same detection time point were compared. The results showed that there was no significant difference in body weight between the two groups at each detection time point, indicating that rhFGF21 did not affect the body weight of normal mice. There was no statistical difference in body weight among the four groups of mice, DM+NS, DM+FGF21, DM+Flu, and DM+Ins (all P>0.05). The above results showed that the three drugs did not affect the body weight of diabetic mice.

[0152] 3.2 rhFGF21 improves depressive-like behavior in STZ-induced diabetic mice

[0153] After 2 weeks of drug treatment, the open field test (OFT), tail suspension test (TST) and forced swimming test (FST) were performed on the six groups of mice: NS, FGF21, DM+NS, DM+FGF21, DM+Flu, and DM+Ins. The test results are shown in Figure 1 .

[0154] Depend on Figure 1The test results showed that in the open field test (OFT), compared with the STZ mice treated with saline, the STZ mice treated with rhFGF21 traveled a longer distance in the open field. In the tail suspension test (TST), the immobility time of mice was shorter after rhFGF21 and insulin treatment. In the forced swimming test (FST), the immobility time of mice treated with rhFGF21, fluoxetine, and insulin was shortened. This shows that rhFGF21 can effectively improve the depressive-like behavior of STZ-induced diabetic mice.

[0155] 3.3 rhFGF21 reverses the increase in endogenous FGF21 levels in the brain induced by high glucose

[0156] After 2 weeks of treatment, the expression levels of endogenous FGF21 in the hippocampus and prefrontal cortex of the six groups of mice (NS, FGF21, DM+NS, DM+FGF21, DM+Flu, DM+Ins) were detected. The test results are shown in Figure 2 .

[0157] Depend on Figure 2 The test results showed that there was no statistical difference in the expression level of endogenous FGF21 in the hippocampus and prefrontal cortex of mice in the NS group and the FGF21 group. Compared with the DM+NS group, the expression level of endogenous FGF21 in the hippocampus of mice in the DM+FGF21 group and the DM+Ins group was lower, while there was no statistical difference in the expression level of endogenous FGF21 in the hippocampus of mice in the DM+Flu group and the DM+NS group. Compared with the DM+NS group, the expression level of endogenous FGF21 in the prefrontal cortex of mice in the DM+FGF21 group, the DM+Flu group and the DM+Ins group was lower.

[0158] rhFGF21 reduces STZ-induced hyperglycemia in mice, but it does not affect the weight loss of STZ-induced diabetic mice, and rhFGF21 has no effect on the weight of normal mice, suggesting that the rhFGF21 dose used in the present invention is safe and effective. Importantly, rhFGF21 effectively improves the physical fitness and depressive-like behavior of STZ-induced diabetic mice. These therapeutic effects of rhFGF21 on diabetic model mice suggest that it may be used in patients with diabetes and depression in the future. The present invention also found that the endogenous FGF21 levels in the hippocampus and prefrontal cortex of high-sugar-induced diabetic mice were increased, and exogenous rhFGF21 treatment could reverse the above changes.

[0159] The following will further explore whether rhFGF21 has an improving effect on neurovascular unit damage caused by high glucose:

[0160] 3.4 rhFGF21 improves cerebral blood perfusion in diabetic mice

[0161] After the treatment, the cerebral blood flow of the six groups of mice, NS, FGF21, DM+NS, DM+FGF21, DM+Flu, and DM+Ins, was recorded using a laser speckle blood flow imager. The test results are shown in Figure 3 .

[0162] Depend on Figure 3 The test results showed that there was no statistical difference in cerebral blood perfusion between the FGF21 group and the NS group, indicating that rhFGF21 did not affect the cerebral blood perfusion of normal mice. Compared with the DM+NS group, the cerebral blood perfusion of the DM+FGF21 group was significantly increased, but the cerebral perfusion of the DM+Flu group and the DM+Ins group was not significantly increased, indicating that rhFGF21 can reverse the high glucose-induced decrease in cerebral blood perfusion and improve the decreased cerebrovascular reactivity caused by diabetes, but neither insulin nor fluoxetine can reverse the high glucose-induced decrease in cerebral blood perfusion.

[0163] 3.5 rhFGF21 improves brain endothelial cell dysfunction in diabetic mice

[0164] Western blot was used to detect the expression levels of vWF, tPA, and PAI-1 in the hippocampus and prefrontal cortex of mice in the six groups of NS, FGF21, DM+NS, DM+FGF21, DM+Flu, and DM+Ins. Figure 4 shown).

[0165] Depend on Figure 4 The test results showed that compared with the NS group mice, the expression level of vWF in the hippocampus and prefrontal cortex of the DM+NS group mice was reduced, and the administration of rhFGF21 could reverse the above changes ( Figure 4 A& Figure 4 D). Compared with the NS group, the tPA expression levels in the hippocampus and prefrontal cortex of the DM+NS group mice increased, and the administration of rhFGF21 could reverse the above changes ( Figure 4 B& Figure 4 E). Compared with the NS group, the expression level of PAI-1 in the hippocampus and prefrontal cortex of the DM+NS group mice was reduced, and the administration of rhFGF21 could reverse the above changes ( Figure 4 C& Figure 4 F).

[0166] Immunofluorescence technique was used to detect the expression levels of eNOS in the hippocampal endothelial cells of the six groups of mice. Figure 5 A) Total expression level of eNOS in hippocampus ( Figure 5 B) The expression level of eNOS in endothelial cells in the prefrontal cortex ( Figure 5 C) Total expression level of eNOS in the prefrontal cortex ( Figure 5 D).

[0167] Compared with the NS group, the expression level of eNOS in CD31+ endothelial cells in the hippocampus and prefrontal cortex of the DM+NS group mice was increased, and rhFGF21 treatment could reverse the above changes. Compared with the NS group, the total expression level of eNOS in the hippocampus and prefrontal cortex of the DM+NS group mice was increased, and rhFGF21 treatment could reverse the above changes.

[0168] 3.6 rhFGF21 alleviates high glucose-induced blood-brain barrier damage

[0169] Western blot was used to detect the expression levels of ZO-1, claudin5, PDGFβ, and AQP4 in the hippocampus of the six groups of mice. Figure 6 AD), compared with the NS group, the expression of ZO-1 in the hippocampus of the DM+NS group was reduced, and the treatment with rhFGF21, fluoxetine, and insulin could reverse the above changes ( Figure 6 A). Compared with the NS group, the expression of claudin5 and PDGFβ in the hippocampus of the DM+NS group mice was reduced, and rhFGF21 treatment was able to reverse the above changes ( Figure 6 B& Figure 6 C). Compared with the NS group, the expression of AQP4 in the hippocampus of the DM+NS group was reduced, and treatment with rhFGF21, fluoxetine, and insulin could not reverse the above changes ( Figure 6 D). Compared with the NS group, the expression of ZO-1, claudin5, and PDGFβ in the prefrontal cortex of the DM+NS group was reduced, and treatment with rhFGF21, fluoxetine, and insulin could reverse the above changes ( Figure 6 EG). Compared with the NS group, the expression of AQP4 in the hippocampus of the DM+NS group was reduced, and treatment with rhFGF21, fluoxetine, and insulin could not reverse the above changes ( Figure 6 H).

[0170] 3.7 rhFGF21 reduces high glucose-induced astrocyte proliferation

[0171] Immunofluorescence was used to detect the changes in the number of GFAP-positive astrocytes in the hippocampus and prefrontal cortex of the six groups of mice. Figure 7 ), compared with the NS group mice, the DM+NS group mice had astrocyte proliferation in the hippocampus, and rhFGF21, fluoxetine, and insulin could reverse the above changes ( Figure 7 A). Compared with the NS group mice, the DM+NS group mice had astrocyte proliferation in the prefrontal cortex, and rhFGF21, fluoxetine, and insulin were able to reverse the above changes ( Figure 7 B).

[0172] 3.8 Effects of rhFGF21 on neuronal function in diabetic mice

[0173] Immunofluorescence technique was used to detect the number of NeuN-positive neurons in the hippocampus and prefrontal cortex of the six groups of mice, and western blot technique was used to detect the expression of synaptic proteins PSD95 and TSP-1 in the hippocampus and prefrontal cortex of the six groups of mice. Figure 8 ).

[0174] There was no statistical difference in the number of hippocampal neurons between the DM+NS group and the NS group, and rhFGF21, fluoxetine, and insulin had no significant effect on the number of hippocampal neurons in diabetic mice ( Figure 8 A). Compared with the NS group, the expression of PSD95 in the hippocampus of the DM+NS group mice was reduced, and administration of rhFGF21 could reverse the above changes ( Figure 8 B). There was no statistical difference in TSP-1 expression in the hippocampus between the DM+NS group and the NS group, and rhFGF21, fluoxetine, and insulin had no significant effect on TSP-1 expression in the hippocampus of diabetic mice ( Figure 8 C). There was no statistical difference in the number of neurons in the prefrontal cortex between the DM+NS group and the NS group, and rhFGF21, fluoxetine, and insulin had no significant effect on the number of neurons in the prefrontal cortex of diabetic mice ( Figure 8 D). Compared with the NS group, the expression of PSD95 in the prefrontal cortex of the DM+NS group mice was reduced, and the administration of rhFGF21, fluoxetine, and insulin could reverse the above changes ( Figure 8 E). Compared with the NS group, the expression of TSP-1 in the prefrontal cortex of the DM+NS group mice was reduced, and the administration of rhFGF21, fluoxetine, and insulin could reverse the above changes ( Figure 8 F).

[0175] The present invention first discovered that rhFGF21 improves cerebral blood perfusion and brain endothelial cell dysfunction in diabetic mice, and reduces the expression reduction of tight junction proteins ZO-1 and Claudin5 and reactive astrocyte proliferation induced by high glucose. At the same time, it was found that rhFGF21 can upregulate the expression of synaptic protein PSD95 in neurons in the hippocampus and prefrontal regions of diabetic mice, but it has no significant effect on the number of neurons in the hippocampus and prefrontal regions of diabetic mice. In short, rhFGF21 reduces the damage of neurovascular units caused by high glucose, which may be one of the potential mechanisms for rhFGF21 to improve diabetic brain complications.

[0176] The following will further explore the neurobiological mechanism by which rhFGF21 improves the depressive-like behavior of diabetic mice:

[0177] 3.9 rhFGF21 alleviates oxidative stress in the brain of diabetic mice

[0178] Biochemical kits were used to detect the activities of CAT and SOD in the hippocampus and prefrontal cortex, and the contents of GSH and MDA in the six groups of mice after treatment. Fig. 9 ).

[0179] Compared with the NS group, the CAT and SOD activities in the hippocampus and prefrontal cortex of the DM+NS group were lower, while the MDA level was higher. rhFGF21 reversed the above changes (hippocampus: Fig. 9 A& Fig. 9 B. Fig. 9 D, frontal lobe: Fig. 9 E& Fig. 9 F. Fig. 9 H), rhFGF21 alleviated the high glucose-induced decrease in CAT and SOD activities and increase in MDA production. There was no significant statistical difference in the GSH content in the hippocampus and prefrontal cortex between the DM+NS group and the NS group, and rhFGF21, fluoxetine, and insulin had no significant effect on the GSH content in the hippocampus of diabetic mice ( Fig. 9 C& Fig. 9 G). It can be concluded that rhFGF21 has a better anti-oxidative stress effect than fluoxetine and insulin in the prefrontal cortex of diabetic mice.

[0180] Western blot was used to detect the expression levels of Nrf2, NQO1, SOD2, and HO-1 in the hippocampus and prefrontal cortex of the six groups of mice after treatment. Fig.10 Compared with the NS group, the expression of Nrf2 in the hippocampus of the DM+NS group was reduced, and rhFGF21, fluoxetine, and insulin could reverse the above changes ( Fig.10 A). Compared with the NS group, the expression of HO-1 in the hippocampus of the DM+NS group mice was reduced, and rhFGF21 and insulin could reverse the above changes ( Fig.10 B). There was no significant statistical difference in the expression level of NQO1 in the hippocampus between the DM+NS group and the NS group, and rhFGF21, fluoxetine, and insulin had no significant effect on the expression of NQO1 in the hippocampus of diabetic mice ( Fig.10 C). Compared with the NS group, the expression of SOD2 in the hippocampus of the DM+NS group mice was reduced, and rhFGF21 and fluoxetine could reverse the above changes ( Fig.10 C). Compared with the NS group mice, the expression of Nrf2 in the prefrontal cortex of the DM+NS group mice was reduced, and rhFGF21 reversed the above changes ( Fig.10 D). Compared with the NS group mice, the expression of HO-1, NQO1, and SOD2 in the prefrontal cortex of the DM+NS group mice was reduced, and rhFGF21 and insulin could reverse the above changes ( Fig.10 E& Fig.10 F).

[0181] It can be concluded that rhFGF21 can upregulate the Nrf2 pathway in the hippocampus and prefrontal cortex of diabetic mice to play an anti-oxidative stress role, and its anti-oxidative stress effect is better than fluoxetine and insulin.

[0182] 3.10 rhFGF21 alleviates glutamate-glutamine cycle disorder in the brain of diabetic mice

[0183] Western blot was used to detect the expression levels of glutamate transporters GLAST and GLT-1 in the hippocampus of the six groups of mice. Fig.11 A) and the expression levels of glutamate transporters GLAST and GLT-1 in the prefrontal cortex ( Fig.11 B).

[0184] Compared with the NS group, the expression of GLAST and GLT-1 in the hippocampus of the DM+NS group was reduced, while the glutamate content was increased. rhFGF21, fluoxetine, and insulin could reverse the above changes ( Fig.11 A). Compared with the NS group mice, the expression of GLAST in the prefrontal cortex of the DM+NS group mice was reduced and glutamate was increased. rhFGF21, fluoxetine and insulin could reverse the above changes ( Fig.11 B). Compared with the NS group mice, the expression of GLT-1 in the prefrontal cortex of the DM+NS group mice was reduced, and rhFGF21 and insulin could reverse the above changes ( Fig.11 B). It can be concluded that rhFGF21 and insulin can reverse the high glucose-induced glutamate metabolism disorder in the prefrontal cortex of mice.

[0185] 3.11rhFGF21 alleviates lactate metabolism disorder in the brain of diabetic mice

[0186] Western blot was used to detect the expression levels of lactate transporters MCT1 and MCT4 in the hippocampus and prefrontal cortex of the six groups of mice. Fig.12 A, B), compared with the NS group, the expression of MCT1 and MCT4 in the hippocampus of the DM+NS group mice was reduced, and rhFGF21 and fluoxetine could reverse the above changes. Compared with the NS group mice, the lactic acid in the hippocampus of the DM+NS group mice was increased, and rhFGF21 and insulin could reverse the above changes ( Fig.12 A). Compared with NS mice, the expression of MCT1 and MCT4 in the prefrontal cortex of DM+NS mice was reduced, and rhFGF21, fluoxetine, and insulin could reverse the above changes. Compared with NS mice, the lactic acid in the prefrontal cortex of DM+NS mice was increased, and rhFGF21 and insulin could reverse the above changes ( Fig.12 B).

[0187] 3.12 Comparison of the mechanisms of different drugs in improving depressive-like behavior in diabetic mice

[0188] The effects of different drugs on improving endothelial cell dysfunction, improving blood-brain barrier damage, anti-oxidative stress, improving glutamate metabolism disorders and lactate metabolism disorders were summarized (see Table 3). It was found that rhFGF21 could increase the whole brain blood perfusion of diabetic mice, but fluoxetine and insulin did not have this effect. At the same time, rhFGF21 improved endothelial cell dysfunction in the hippocampus and prefrontal regions of diabetic mice, and its effect was better than fluoxetine and insulin. Insulin mainly improved endothelial cell dysfunction in the hippocampus and prefrontal regions by increasing vWF and reducing tPA, while fluoxetine further improved endothelial cell dysfunction in the hippocampus and prefrontal regions by increasing PAI-1. rhFGF21 can increase the expression levels of vWF and PAI-1 and reduce the expression level of tPA. All three drugs can increase the expression of eNOS in endothelial cells. The effect of rhFGF21 in improving blood-brain barrier damage in the hippocampus and prefrontal regions of diabetic mice is better than fluoxetine and insulin. rhFGF21 can increase the expression of Claudin5 and PDGFβ in the hippocampus, while fluoxetine and insulin cannot increase Claudin5 and PDGFβ in the hippocampus. In this study, no significant difference was found between fluoxetine and insulin in the protective effect on the blood-brain barrier, suggesting that the reduction of blood-brain barrier damage may be a manifestation accompanying the antidepressant process of fluoxetine and insulin rather than a specific target. rhFGF21, fluoxetine and insulin can reverse the excessive activation of astrocytes induced by high glucose, suggesting that improving the dysfunction of astrocytes induced by high glucose may be a common target of antidepressants and hypoglycemic drugs to improve diabetes-associated depression. The test results showed that rhFGF21, fluoxetine and insulin can reduce the glutamate content in the hippocampus and prefrontal regions of diabetic mice. rhFGF21 and insulin can reduce the increase of lactic acid content in the hippocampus and prefrontal cortex of mice induced by high glucose, but fluoxetine cannot reduce the increase of lactic acid content in the hippocampus and prefrontal cortex of mice induced by high glucose, indicating that the use of hypoglycemic drugs can specifically improve the lactic acid metabolism disorder induced by high glucose, while fluoxetine does not have the effect of improving lactic acid metabolism disorder. The test results show that fluoxetine can increase the expression of lactate transporters MCT1 and MCT4 in the hippocampus and prefrontal cortex of diabetic mice. Therefore, it is speculated that the ways in which hypoglycemic drugs such as insulin and rhFGF21 reduce the lactic acid content in the brain of diabetic mice are diverse, not just increasing the expression level of lactate transporters MCT1 and MCT4 in the brain of diabetic mice. The anti-oxidative stress effect of rhFGF21 is better than that of fluoxetine and insulin, which is mainly manifested in increasing the activity of CAT and SOD2 in the brain of diabetic mice and reducing the content of MDA in the brain of diabetic mice, while fluoxetine and insulin have no such effects.At the same time, it was found that rhFGF21 could upregulate the expression levels of Nrf2, HO-1, and SOD2 proteins in the hippocampus and prefrontal cortex of diabetic mice, while insulin and fluoxetine only upregulated the Nrf2 pathway in the hippocampus of diabetic mice, but had no significant upregulation effect on the Nrf2 pathway in the prefrontal cortex, suggesting that rhFGF21 has a better antioxidant stress resistance than fluoxetine and insulin. In this study, different drug treatments did not affect the number of neurons in diabetic mice. However, rhFGF21 could increase the expression level of PSD95 in the hippocampus and prefrontal cortex of diabetic mice, while fluoxetine and insulin only increased the PSD95 level in the prefrontal cortex of diabetes.

[0189] Table 3 Comparison of the mechanisms of different drugs in improving depressive-like behavior in diabetic mice

[0190]

[0191]

[0192] The present invention first discovered that rhFGF21 has the effects of anti-oxidative stress and reducing blood-brain barrier damage in the hippocampus and prefrontal regions of diabetic mice. At the same time, it can inhibit the excessive activation of astrocytes in the hippocampus and prefrontal regions of diabetic mice, reduce the production of glutamate and lactic acid in the hippocampus and prefrontal regions of diabetic mice, and ultimately improve the depressive-like behavior of diabetic mice. Fig.13 This is a diagram of the neurobiological mechanism of rhFGF21 improving diabetic mice based on the research in the present invention.

[0193] By summarizing and comparing the effects of three drugs on anti-oxidative stress, improving endothelial cell dysfunction, improving blood-brain barrier, improving glutamate metabolism disorder and lactate metabolism disorder, it was found that rhFGF21 has a stronger anti-oxidative stress effect than fluoxetine and insulin. It can upregulate the Nrf2 / HO-1 pathway in the hippocampus and prefrontal cortex of diabetic mice, increase CAT and SOD activity, and reduce the content of MDA. At the same time, rhFGF21 is the only drug among the three drugs that can increase the whole brain blood perfusion of diabetic mice, and its effect of improving endothelial cell dysfunction and protecting the blood-brain barrier is the strongest. It is also found in the present invention that in the effect of improving endothelial cell dysfunction, insulin mainly improves endothelial cell dysfunction by increasing vWF levels and reducing tPA levels, while fluoxetine further improves endothelial cell dysfunction by increasing PAI-1 levels. All three drugs can reduce the excessive activation of astrocytes induced by high sugar, and reduce glutamate metabolism disorders in the hippocampus and prefrontal cortex of diabetic mice. However, only rhFGF21 and insulin could reduce lactate levels in the hippocampus and prefrontal cortex of diabetic mice, suggesting that this may be a specific mechanism by which hypoglycemic drugs improve depressive-like behavior in diabetic mice.

[0194] In summary, the present invention found that rhFGF21 reduces blood sugar in diabetic mice and relieves the level of oxidative stress in the brain of diabetic mice, reducing endothelial cell damage and dysfunction caused by oxidative stress. At the same time, rhFGF21 increases the expression of tight junction proteins ZO-1, claudin5 and pericyte marker PDGFβ in the blood-brain barrier of diabetic mice, reduces the over-activation of astrocytes and glutamate metabolism disorders and lactate metabolism disorders in the brain of diabetic mice, increases the expression of neuronal synaptic protein PSD95, and finally improves the depressive-like behavior of diabetic mice. Compared with fluoxetine and insulin, rhFGF21 has a stronger effect of resisting oxidative stress, increasing whole brain blood perfusion, improving brain endothelial cell dysfunction and protecting the blood-brain barrier, suggesting that it has advantages in the treatment of cerebrovascular diseases. At the same time, improving lactate metabolism dysfunction may be one of the important mechanisms for hypoglycemic drugs to improve the depressive-like behavior of diabetic mice.

[0195] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A use of rhFGF21 in the preparation of a drug for treating diabetes-associated depression.

2. The use according to claim 1, It is characterized in that The rhFGF21 is used for preparing medicine for lowering blood sugar of diabetes and improving its depressive-like behavior.

3. The use according to claim 2, It is characterized in that The rhFGF21 is used for preparing a medicine for alleviating high-glucose-induced neurovascular unit damage.

4. The use according to claim 3, It is characterized in that The rhFGF21 is used for preparing a medicine with an anti-oxidative stress effect.

5. The use according to claim 4, It is characterized in that The rhFGF21 is used to prepare a drug for up-regulating the Nrf2 / HO-1 pathway in the brain, increasing the activities of CAT and SOD in the brain, and reducing the content of MDA.

6. The use according to claim 5, It is characterized in that The rhFGF21 is used to prepare a drug for improving endothelial cell dysfunction and blood-brain barrier damage induced by high glucose and oxidative stress.

7. The use according to claim 2 or 6, It is characterized in that The rhFGF21 is used for preparing medicine for increasing the amount of cerebral blood perfusion.

8. The use according to claim 7, It is characterized in that The rhFGF21 is used to prepare a drug for alleviating the reduced expression of tight junction proteins ZO-1, Claudin5, and pericyte marker PDGFβ and the over-activated proliferation of astrocytes induced by high glucose.

9. The use according to claim 8, It is characterized in that The rhFGF21 is used to prepare a drug for improving high-glucose-induced glutamate metabolism disorder and lactate metabolism disorder in the brain.

10. The use according to claim 9, It is characterized in that The rhFGF21 is used for preparing a drug for increasing the expression of neuronal synaptic protein PSD95.